Vienna has welcomed this past week from 1 to 4 December, the International Symposium on Ocular Pharmacology and Therapeutics (ISOPT). The director of the Institute of Retina and Macula of Barcelona, Dr. Jordi Mones, has been a leading participant during the four days of ophtalmological update.
His main contribution was to present the first results and evolution of the phase 1 study, coordinated by the IMIR on Targeting Anti Complement anti C5 therapy for geographic atrophy secondary to age-related macular degeneration.
Another study presented by the director of IMIR was the Targeting platelet Derived (PDGF) and vascular endothelial (VEGF) growth factors for neovascular AMD Phase I and Phase II. Also gave an update on the Fusion Regimen for Ranibizumab; combination of OCT guided retreatment with fixed retreatment. (PRN+FIXED) for wet AMD and was in the presentation and discussion of cases in the working group on data showing wet AMD study ICG silent polypoidal vasculopathy with favorable response to thermal laser therapy.
Dr. Mones also chaired the session on dry AMD free papers and free papers session on wet AMD and actively participated in the ERAB Advisory Group Meeting on retinal vein occlusion.